Sight Sciences, Inc. (Nasdaq: SGHT) reported select preliminary, unaudited financial highlights for Q4 and full year 2025.
Total revenue for Q4 2025 is expected to be around $20.3 million to $20.4 million, showing a 7% increase from the previous year.
The company's cash and cash equivalents as of December 31, 2025, were approximately $92 million.
Revenue Growth
Q4 2025 revenue increased by 7% compared to the prior year period.
Cash Position
The company had approximately $92 million in cash and cash equivalents as of December 31, 2025.
Dry Eye Revenues
Dry Eye revenues are expected to be approximately $0.7 million, showing a significant increase from the previous year period.
- The company's strong revenue growth in Q4 2025 showcases promising performance and potential for future expansion.
- The increase in Dry Eye revenues indicates successful market penetration and growth in this segment.
Sight Sciences demonstrated positive growth in Q4 2025 with increased revenues and a healthy cash position. The focus on innovative eyecare technologies seems to be driving the company's success.